AGIO
NASDAQAgios Pharmaceuticals Inc.
Price$28.79+0.73 (+2.60%)
01:30 PM07:45 PM
News · 26 weeks52-14%
2025-12-072026-05-31
Mix2390d
- Insider7(30%)
- Other7(30%)
- Earnings4(17%)
- SEC Filings4(17%)
- Analyst1(4%)
Latest news
25 items- PRAgios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor CevidoplenibAgios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios' rare hematology portfolio with expansion into immune thrombocytopenia, unlocking up to $1 billion in peak U.S. sales potentialOscotec will receive $25.0 million upfront, with future payments tied to development, regulatory, and commercial milestones, as well as tiered royalties on future net salesAgios will host investor conference call and webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit
- PRAgios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic SyndromesResults did not meet predefined threshold to support further development in LR-MDSTebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that it will not advance tebapivat, a next-generation oral pyruvate kinase (PK) activator, in lower-risk myelodysplastic syndromes (LR-MDS). This decision follows results from its Phase 2b trial that did not meet the company's predefined threshold to support further development in this indication. The open-label, mu
- PRAvanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with ThalassaemiaAvanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation fo
- PRAgios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with ThalassemiaPYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemiaMitapivat is now approved for thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and EUAvanzanite Bioscience B.V., a specialty pharmaceutical company, will continue to distribute and commercialize PYRUKYND in Europe CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the European Commission (EC) has granted marketing authorization for PYRUKYND® (mitapivat),
- PRAgios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell DiseasesNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing transfusion burden in sickle cell disease CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the U.S. accelerated approval of mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease.
- PRAgios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic AnemiasDetailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 2026 on Saturday, June 13, at 9:00 a.m. ET (3:00 p.m. CEST) CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate kinase (PK) activator, will be featured in oral and poster presentations during the 31st European Hematology Association (EHA) Congress (EHA 2026) in Stockhol
- SECSEC Form SCHEDULE 13G filed by Agios Pharmaceuticals Inc.SCHEDULE 13G - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
- SECSEC Form 10-Q filed by Agios Pharmaceuticals Inc.10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- SECAgios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- PRAgios Reports First Quarter 2026 Financial Results and Provides Business UpdateMitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025Strong initial U.S. commercial launch of AQVESME in thalassemia, with 242 prescriptions written as of March 31, 2026Company plans to submit mitapivat sNDA for sickle cell disease in the second quarter of 2026Pipeline advancing to multiple value-driving inflection points in 2026, including two Phase 2 readouts for next-generation PK activator tebapivat$1.0 billion in cash, cash equivalents, and marketable securities as of March 31, 2026 CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:
- SECSEC Form DEFA14A filed by Agios Pharmaceuticals Inc.DEFA14A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- SECSEC Form DEF 14A filed by Agios Pharmaceuticals Inc.DEF 14A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- ANALYSTH.C. Wainwright reiterated coverage on Agios Pharma with a new price targetH.C. Wainwright reiterated coverage of Agios Pharma with a rating of Buy and set a new price target of $50.00 from $65.00 previously
- INSIDERSEC Form 4 filed by Burns James William4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Gheuens Sarah4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Jones Cecilia4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Milanova Tsveta4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Viswanadhan Krishnan4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Goff Brian4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRAgios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ETCAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Wednesday, April 29, 2026, at 8:00 a.m. ET to report its first quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company's website approximately two hours after the event. About Agios: Fueled by Connections
- PRAgios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDACompany has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit mitapivat sNDA in sickle cell disease in the coming months, and is actively working with FDA to achieve alignment on confirmatory trial required for submission CAMBRIDGE, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that it will pursue U.S. accelerated approval for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease, following completion of its pre-su
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Agios Pharmaceuticals Inc.SCHEDULE 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
- INSIDERChief Corp Dev & Strategy Viswanadhan Krishnan sold $82,260 worth of shares (2,959 units at $27.80) and converted options into 8,100 shares (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERPrincipal Accounting Officer Washburn Theodore James Jr. sold $152,255 worth of shares (5,272 units at $28.88), decreasing direct ownership by 86% to 868 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERChief Medical Officer Gheuens Sarah converted options into 13,666 shares and sold $117,433 worth of shares (4,055 units at $28.96), increasing direct ownership by 15% to 74,406 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
AGIO FAQ
7 questionsWhat does Agios Pharmaceuticals Inc. do?
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat...Where does AGIO stock trade?
Agios Pharmaceuticals Inc. (AGIO) is listed on NASDAQ.What sector and industry is AGIO in?
Agios Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Agios Pharmaceuticals Inc. go public?
Agios Pharmaceuticals Inc. (AGIO) completed its IPO in 2013.What are analysts saying about AGIO?
Agios Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2026-04-20. Recent price targets range from $2800.00 to $3400.00.What companies are similar to AGIO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AGIO side-by-side with any of them on Quantisnow.How can I track AGIO on Quantisnow?
Quantisnow aggregates Agios Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AGIO to receive live email and push alerts on every new disclosure.